Coherus Oncology Secures $50M to Fuel Innovative Cancer Drug Pipeline

REDWOOD CITY, CA – February 17, 2026 – Coherus Oncology, Inc. has successfully closed a public offering of common stock, injecting approximately $50.1 million in gross proceeds into its operations. The move, backed by a consortium of prominent healthcare-dedicated investors, marks a pivotal moment in the company's ambitious transformation from a biosimilar manufacturer into a focused, innovative oncology drug developer.

The financing saw the sale of 28.6 million shares at $1.75 per share and was led by new investors Janus Henderson Investors, HBM Healthcare Investments, and Samsara BioCapital. The influx of capital is earmarked to accelerate the commercialization of its recently approved cancer therapy, LOQTORZI®, and to advance a promising pipeline of clinical-stage candidates targeting a range of difficult-to-treat cancers.

A Strategic Pivot Solidified

This public offering is more than just a financial transaction; it is a powerful affirmation of Coherus's dramatic strategic overhaul. Over the past two years, the company has methodically shed its identity as a biosimilar-focused entity to emerge as a pure-play oncology innovator. This transformation has included strengthening its balance sheet and reducing its debt by over 80%.

In a statement accompanying the announcement, Chairman and Chief Executive Officer Denny Lanfear highlighted the significance of the move. “Over the last two years we strengthened our balance sheet, reduced our debt by over 80%, and transformed Coherus from a biosimilar company to a clinical-stage Biotech focused on innovative oncology,” he said. “With this financing we make further progress in rebuilding our capitalization table to support our expanding clinical development programs and upcoming data readouts, while funding commercial efforts to increase market penetration and revenue generation.”

The strategic pivot was further underscored by the company's planned divestiture of its UDENYCA biosimilar franchise, signaling a full commitment to the high-risk, high-reward world of novel cancer therapeutics. The net proceeds from this offering, estimated at around $47 million after expenses, provide the necessary fuel to power this specialized focus.

Investor Confidence in a Thawing Biotech Market

The leadership of the offering by specialized funds like Janus Henderson Investors, HBM Healthcare Investments, and Samsara BioCapital sends a strong signal of confidence. These firms are known for their deep scientific diligence and focus on companies with the potential to significantly alter the practice of medicine. Their investment serves as a crucial validation of Coherus’s scientific platform and its potential to deliver value in the competitive oncology space.

This financing comes as the broader biotech sector shows signs of a robust recovery after a prolonged downturn. After a period described by some as a "nuclear financial winter," investors are once again rewarding companies with high-quality, innovative assets and clear paths to market. Oncology remains a primary area of investment focus, driven by continuous scientific breakthroughs and significant unmet patient needs.

Wall Street analysts appear to share this optimistic outlook. Despite the offering price of $1.75 per share, which represents a discount to recent trading, the consensus analyst rating for Coherus (NASDAQ: CHRS) remains a "Strong Buy." The median 12-month price target among analysts sits at $6.50, with some, like Oppenheimer, initiating coverage with an "Outperform" rating and a $10 price target. This suggests that while the offering creates near-term dilution for existing shareholders, market experts believe the long-term growth trajectory enabled by the funding far outweighs it.

Powering a Promising Oncology Pipeline

The capital raised will be instrumental in supporting Coherus’s two-pronged growth strategy: maximizing the commercial success of LOQTORZI® and advancing its mid-stage pipeline.

LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, stands as the company's commercial cornerstone. It holds the distinction of being the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of nasopharyngeal carcinoma (NPC), a rare and aggressive head and neck cancer. Approved in late 2023, the drug is now being rolled out across the United States, and the new funding will be critical for marketing, sales, and educational efforts to establish it as the standard of care.

Beyond its commercial asset, Coherus is advancing a pipeline of innovative immunotherapies designed to enhance the body's own immune response to fight cancer:

• Tagmokitug: This highly selective anti-CCR8 antibody is engineered to deplete tumor-infiltrating regulatory T-cells, which often suppress the immune system's ability to attack cancer. Currently in Phase 1b/2a studies for advanced solid tumors, it has already shown early signs of clinical activity. In a significant development, Coherus recently announced a clinical collaboration with Johnson & Johnson to evaluate Tagmokitug in combination with a T-cell engaging bispecific antibody for metastatic prostate cancer, expanding its potential application.

• Casdozokitug: This novel antibody targets IL-27, a cytokine that can inhibit anti-tumor immune responses. It is being evaluated in a Phase 2 study for first-line hepatocellular carcinoma (HCC), or liver cancer. The drug has already received Orphan Drug and Fast Track designations from the FDA, which could expedite its development and review process. Early data presented at major oncology conferences have shown promising response rates, positioning it as a potential new option for liver cancer patients.

By securing this financing, Coherus Oncology has not only bolstered its financial position but has also decisively charted its course for the future. The company is now poised to execute on its vision of becoming a leading force in innovative cancer treatment, armed with a commercial-stage product, a promising clinical pipeline, and the renewed confidence of the investment community.